Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

X4 Pharmaceuticals (XFOR) EBT (2018 - 2025)

X4 Pharmaceuticals (XFOR) has disclosed EBT for 8 consecutive years, with -$29.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBT rose 18.64% year-over-year to -$29.8 million, compared with a TTM value of -$94.8 million through Sep 2025, down 468.53%, and an annual FY2024 reading of -$37.1 million, up 63.26% over the prior year.
  • EBT was -$29.8 million for Q3 2025 at X4 Pharmaceuticals, down from -$25.7 million in the prior quarter.
  • Across five years, EBT topped out at $90.9 million in Q2 2024 and bottomed at -$55.7 million in Q2 2023.
  • Average EBT over 5 years is -$19.8 million, with a median of -$21.9 million recorded in 2022.
  • Peak annual rise in EBT hit 263.12% in 2024, while the deepest fall reached 1509.52% in 2024.
  • Year by year, EBT stood at -$30.2 million in 2021, then grew by 3.69% to -$29.1 million in 2022, then skyrocketed by 34.35% to -$19.1 million in 2023, then tumbled by 107.17% to -$39.6 million in 2024, then increased by 24.56% to -$29.8 million in 2025.
  • Business Quant data shows EBT for XFOR at -$29.8 million in Q3 2025, -$25.7 million in Q2 2025, and $316000.0 in Q1 2025.